Kathleen E. Sullivan

Kathleen E. Sullivan

Auto-generated profile, based on publicly available information

Kathleen E. Sullivan

Department of Food Science and Human Nutrition University of Florida Gainesville Florida USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2010 in Zoo Biology
Verified
Journal Article
Closed access
PDF file
KSKathleen Sullivan
Kathleen Sullivan
EHEric van Heugten
Eric van Heugten
Kimberly Ange-van HeugtenKimberly Ange-van Heugten
Kimberly Ange-van Heugten
MPMatthew H. Poore
Matthew H. Poore
Ellen S. DierenfeldEllen S. Dierenfeld
Ellen S. Dierenfeld
BWBarbara Wolfe
Barbara Wolfe


27 July 2022 in Journal of Animal Physiology and Animal Nutrition
Verified
Journal Article
Open access
KSKathleen E. Sullivan
Kathleen E. Sullivan
SLShana R. Lavin
Shana R. Lavin
SLShannon Livingston
Shannon Livingston
MKMitchell Knutson
Mitchell Knutson
EVEduardo V. Valdes
Eduardo V. Valdes
LWLori K. Warren
Lori K. Warren
While iron overload disorder (IOD) and related disease states are not considered a common occurrence in domestic equids, these issues appear prevalent in black rhinoceroses under human care. In addressing IOD in black rhinos, altering dietary iron absorption and excretion may be the most globally practical approach. A main option for treatment used across other species such as humans, is chelation therapy using iron‐specific synthetic compounds. As horses may serve as an appropriate digestive model for the endangered rhinoceros, we evaluated the potential use of the oral iron chelatorN,N‐bis(2‐hydroxybenzyl)ethylenediamine‐N,N‐diacetic acid (HBED) in horses for safety and efficacy prior to testing in black rhinoceros. Health and iron digestibility and dynamics were assessed in horses (n = 6) before, and after treatment with HBED (50 mg/kg body weight) for 8 days using a crossover design with serum, faecal and urine collection. A preliminary pharmacokinetic trial was also performed but no trace of HBED was found in serially sampled plasma through 8 h post‐oral dosing. HBED increased urinary iron output in horses compared to control by 0.7% of total iron intake (p < 0.01), for an average of 27 mg urinary iron/day, similar to human chelation goals. Blood chemistry, blood cell counts and overall wellness were not affected by treatment. As healthy horses are able to regulate iron absorption, the lack of change in iron balance is unsurprising. Short‐term HBED administration appeared to be safely tolerated by horses, therefore it was anticipated it would also be safe to administer to black rhinos for the management of iron overload.

1 May 2021 in Journal of Equine Veterinary Science
Verified
Journal Article
Closed access
MDM.R. Di-Lernia
M.R. Di-Lernia
JBJ.M. Bobel
J.M. Bobel
LCLaura Marie Cersosimo
Laura Marie Cersosimo
SLS. Livingston
S. Livingston
EVE.V. Valdes
E.V. Valdes
LWLori Kay Warren
Lori Kay Warren